Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Zelenetz, Andrew D.Barrientos, Jacqueline C.Brown, Jennifer R.Coiffier, BertrandDelgado, JulioEgyed, MiklósGhia, PaoloIllés, ÁrpádJurczak, WojciechMurlton, PaulaMontillo, MarcoMorschhauser, FranckPristupa, Alexander S.Robak, TadeuszSharman, Jeff P.Simpson, DavidSmolej, LukásTausch, EugenAdewoye, Adeboye H.Dreiling, Lyndah K.Kim, YeonheeStilgenbaur, StephanHillmen, Peter2017-08-022017-08-022017Lancet Oncology. - 18 (2017), p. 297-311. -Lancet Oncol. - 1470-20451470-2045http://hdl.handle.net/2437/242826Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialfolyóiratcikkopen access pre-print és post-printhttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM070024OrvostudományokKlinikai orvostudományokElsevierhttps://www.sciencedirect.com/science/article/pii/S1470204516306714?via%3Dihub2018-05-17